Erythropoetin treatment can increase 2,3-diphosphoglycerate levels in red blood cells

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Sandhagen B.) > Erythropoetin treat...

Birgegård, Gunnar,1944-Uppsala universitet,Institutionen för medicinska vetenskaper,Hematologi (författare)

Erythropoetin treatment can increase 2,3-diphosphoglycerate levels in red blood cells

Artikel/kapitelEngelska2001

Förlag, utgivningsår, omfång ...

2001
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:uu-137255
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-137255URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Some patients experience an improved well-being during treatment with recombinant human erythropoietin even with an unchanged Hb level. We have hypothesized that this may not be only a placebo effect. 2,3-diphosphoglycerate (2,3-DPG) in red blood cells increases in response to anaemia/hypoxia and causes a shift of the oxygen dissociation curve, allowing a more effective oxygen delivery. We have investigated red cell 2,3-DPG concentrations during erythropoietin treatment in healthy volunteers as a mediator of a possible physiological explanation. Thirteen healthy subjects with no iron deficiency were recruited and randomly assigned to a treatment group comprising five males and three females and a control group including three males and two females. The treatment group was treated with erythropoietin (Recormon), 20 IE/kg subcutaneously three times/week for 4 weeks. Blood samples were collected at each injection day and 10 days after the last injection and at corresponding times in the control group. B-Hb, red cell 2,3-DPG and P50 were measured by standard techniques and oxygen-releasing capacity was calculated. RESULTS: due to the sampling (26 ml each time, three times/week) the mean Hb level was lowered from 140.5 +/- 5.9 to 128.6 +/- 10.4 g/L in the control group whereas the erythropoietin treatment group maintained a mean Hb level of about 142 g/L (p<0.002). The 2,3-DPG mean level curve as well as that for oxygen releasing capacity also differed significantly between the two groups (p < 0.002), the treatment group showing higher levels. CONCLUSION: treatment with erythropoietin causes an increase in red cell 2,3-DPG levels.

Ämnesord och genrebeteckningar

MEDICINE
MEDICIN

Biuppslag (personer, institutioner, konferenser, titlar ...)

Sandhagen, B. (författare)
Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Sammanhörande titlar

Ingår i:Scandinavian Journal of Clinical and Laboratory Investigation61:5, s. 337-3400036-55131502-7686

Internetlänk

https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-137255

Hitta via bibliotek

Scandinavian Journal of Clinical and Laboratory Investigation (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Birgegård, Gunna ...; Sandhagen, B.

Artiklar i publikationen: Scandinavian Jou ...

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se